Shih‐Hung Yang

566 total citations
37 papers, 412 citations indexed

About

Shih‐Hung Yang is a scholar working on Oncology, Epidemiology and Surgery. According to data from OpenAlex, Shih‐Hung Yang has authored 37 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 15 papers in Epidemiology and 11 papers in Surgery. Recurrent topics in Shih‐Hung Yang's work include Pancreatic and Hepatic Oncology Research (30 papers), Neuroendocrine Tumor Research Advances (14 papers) and Cancer Genomics and Diagnostics (7 papers). Shih‐Hung Yang is often cited by papers focused on Pancreatic and Hepatic Oncology Research (30 papers), Neuroendocrine Tumor Research Advances (14 papers) and Cancer Genomics and Diagnostics (7 papers). Shih‐Hung Yang collaborates with scholars based in Taiwan, China and United States. Shih‐Hung Yang's co-authors include Yu‐Wen Tien, Ming‐Chu Chang, Yu‐Ting Chang, Ting‐Chun Kuo, Sung‐Hsin Kuo, Bang‐Bin Chen, Ann‐Lii Cheng, Yung‐Ming Jeng, Tiffany Ting‐Fang Shih and Chih‐Hung Hsu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Oncogene.

In The Last Decade

Shih‐Hung Yang

36 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shih‐Hung Yang Taiwan 11 286 128 114 70 62 37 412
Ron Korn United States 8 206 0.7× 83 0.6× 104 0.9× 71 1.0× 32 0.5× 26 350
Takako Nirei Japan 9 284 1.0× 103 0.8× 97 0.9× 32 0.5× 85 1.4× 13 435
Li-Na Zhou China 10 191 0.7× 63 0.5× 202 1.8× 47 0.7× 51 0.8× 20 405
Xinjian Huang China 13 172 0.6× 112 0.9× 190 1.7× 34 0.5× 30 0.5× 25 395
Axel Bengtsson Sweden 8 298 1.0× 119 0.9× 93 0.8× 19 0.3× 97 1.6× 11 390
Shengyu Wu China 12 128 0.4× 70 0.5× 151 1.3× 38 0.5× 25 0.4× 29 347
Aiko Nagayama Japan 9 274 1.0× 100 0.8× 74 0.6× 97 1.4× 49 0.8× 27 394
Giulia Orsi Italy 12 220 0.8× 113 0.9× 171 1.5× 28 0.4× 115 1.9× 34 514
Chris Nevala-Plagemann United States 8 280 1.0× 107 0.8× 107 0.9× 15 0.2× 53 0.9× 28 398
Guadalupe Lorenzatti Hiles United States 10 175 0.6× 87 0.7× 224 2.0× 32 0.5× 58 0.9× 16 397

Countries citing papers authored by Shih‐Hung Yang

Since Specialization
Citations

This map shows the geographic impact of Shih‐Hung Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shih‐Hung Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shih‐Hung Yang more than expected).

Fields of papers citing papers by Shih‐Hung Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shih‐Hung Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shih‐Hung Yang. The network helps show where Shih‐Hung Yang may publish in the future.

Co-authorship network of co-authors of Shih‐Hung Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Shih‐Hung Yang. A scholar is included among the top collaborators of Shih‐Hung Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shih‐Hung Yang. Shih‐Hung Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Shih‐Hung, Sung‐Hsin Kuo, Jen‐Chieh Lee, et al.. (2024). Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Cancer Immunology Immunotherapy. 73(11). 227–227. 5 indexed citations
2.
Su, Yung‐Yeh, Nai‐Jung Chiang, Yi‐Hsin Yang, et al.. (2023). Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Cancers. 15(4). 1008–1008. 5 indexed citations
3.
Su, Yung‐Yeh, Nai‐Jung Chiang, Tai‐Jan Chiu, et al.. (2023). Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Biomedical Journal. 47(3). 100696–100696. 1 indexed citations
4.
Su, Yung‐Yeh, Nai‐Jung Chiang, Chung‐Pin Li, et al.. (2022). Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Frontiers in Oncology. 12. 800842–800842. 6 indexed citations
5.
Chen, Bang‐Bin, et al.. (2022). Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. Frontiers in Immunology. 13. 1077840–1077840. 2 indexed citations
6.
7.
Yang, Shih‐Hung, Li‐Chun Lu, Hsiang‐Fong Kao, et al.. (2021). Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. OncoImmunology. 10(1). 1973710–1973710. 6 indexed citations
8.
Su, Yung‐Yeh, Yen‐Feng Chiu, Chung‐Pin Li, et al.. (2021). A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. British Journal of Cancer. 126(7). 1018–1026. 15 indexed citations
9.
Kuo, Ting‐Chun, Ming‐Hsun Wu, Shih‐Hung Yang, et al.. (2021). C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. Oncogene. 40(7). 1242–1254. 29 indexed citations
10.
Wang, Hsiu-Po, Chieh‐Chang Chen, Yu‐Wen Tien, et al.. (2021). Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma. European Radiology. 31(10). 8040–8049. 2 indexed citations
11.
Barve, Minal, Ming‐Shiang Wu, Kathleen F. Pirollo, et al.. (2021). A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.. Journal of Clinical Oncology. 39(15_suppl). 4139–4139. 11 indexed citations
12.
Yang, Shih‐Hung, et al.. (2019). Postoperative Imaging and Tumor Marker Surveillance in Resected Pancreatic Cancer. Journal of Clinical Medicine. 8(8). 1115–1115. 7 indexed citations
13.
Yang, Shih‐Hung, Chiun Hsu, Sung‐Hsin Kuo, et al.. (2019). Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association. 119(1). 97–105. 3 indexed citations
14.
Yang, Shih‐Hung, et al.. (2018). A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research. 38(8). 4805–4812. 2 indexed citations
15.
Yang, Shih‐Hung, Jen‐Chieh Lee, Sung‐Hsin Kuo, et al.. (2017). Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE. 12(7). e0180628–e0180628. 4 indexed citations
16.
17.
Chen, Bang‐Bin, Yu‐Wen Tien, Ming‐Chu Chang, et al.. (2016). PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis. European Journal of Nuclear Medicine and Molecular Imaging. 43(10). 1753–1764. 50 indexed citations
18.
Yang, Shih‐Hung, Ting‐Chun Kuo, Chiun Hsu, et al.. (2016). Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology. 22(32). 7275–7275. 30 indexed citations
19.
Yang, Shih‐Hung, Chih‐Hung Hsu, Jen‐Chieh Lee, et al.. (2013). Nuclear Expression of Glioma-Associated Oncogene Homolog 1 and Nuclear Factor-κB Is Associated with a Poor Prognosis of Pancreatic Cancer. Oncology. 85(2). 86–94. 20 indexed citations
20.
Yang, Shih‐Hung, Yu‐Hsuan Kuo, Yu‐Wen Tien, et al.. (2011). Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology. 81(3-4). 143–150. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ron Korn Breakdown of academic impact, for papers by Takako Nirei Breakdown of academic impact, for papers by Li-Na Zhou Breakdown of academic impact, for papers by Xinjian Huang Breakdown of academic impact, for papers by Axel Bengtsson Breakdown of academic impact, for papers by Shengyu Wu Breakdown of academic impact, for papers by Aiko Nagayama Breakdown of academic impact, for papers by Giulia Orsi Breakdown of academic impact, for papers by Chris Nevala-Plagemann Breakdown of academic impact, for papers by Guadalupe Lorenzatti Hiles
Rankless by CCL
2026